Thrive Earlier Detection, the developer of an early cancer screening blood test invented at JHU, has raised $257m in series B funding.

Thrive Earlier Detection, a US-based cancer screening technology spinout of Johns Hopkins University, collected $257m yesterday in a series B round co-led by Casdin Capital and Section 32.
Bain Capital Life Sciences, a subsidiary of private equity firm Bain Capital, also invested, as did Brown Advisory, Driehaus Capital Management, Intermountain Ventures, Janus Henderson Investors, Lux Capital, Moore Strategic Ventures, Perceptive Advisors, Rock Spring Capital, Sands Capital and undisclosed investors including clients advised by T Rowe Price Associates.
Thrive…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?